| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b56931d402414ac2924944ec413ee2e2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-417
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-417
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44 |
| filingDate |
2003-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4044821f2dcd7b303b2187af12e4ad1d |
| publicationDate |
2005-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03082081-A3 |
| titleOfInvention |
Use of rom production and release inhibitors to treat and prevent intraocular damage |
| abstract |
A method of treating or preventing intraocular damage caused by reactive oxygen metabolites is provided. The method includes identifying a subject presenting the symptoms of proliferative diabetic retinopathy; and administering to at least one eye of the subject a pharmaceutically acceptable solution containing an effective concentration of a compound effective to reduce the amount of ROM in an individual. The compounds effective to reduce the amount of ROM in an individual include histamine and histamine related compounds. The specific disease states characterized by intraocular damage caused by reactive oxygen metabolites include proliferative diabetic retinopathy, preproliferative diabetic retinopathy, proliferative retinopathy, age-related macular degeneration, retinitis pigmentosa, and macular holes. A pharmaceutical composition including a pharmaceutically acceptable ophthalmic solution containing an effective concentration of a compound effective to reduce the amount of ROM in an individual is likewise provided. |
| priorityDate |
2002-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |